hotspot -WSS

hotspot

author：knowledge 2025-09-30 17:59:22 - browse：41419

Illumina said Monday afternoon that its board of directors had approved a spin-off of its cancer test subsidiary Grail, signaling that a nearly four-year-long, $8 billion saga will finally draw to a close this month.

Shares in the newly independent Grail are expected to be distributed on June 24, Illumina said in a statement. Illumina will retain a 14.5% stake in the company, which will trade under the ticker $GRAL.

It’s the second time Illumina has spun off Grail, which initially began as a unit within the DNA sequencing giant in 2015. Illumina turned it into an independent company the following year but then agreed to reacquire it for $8 billion in September 2020.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Why depression after traumatic brain injury is distinct

focus

Wikipedia

focus

WSS

John Green on his newest strategy for fighting tuberculosis

What PEPFAR has meant on the ground in Ukraine

Pharma patents targeted by Biden in move to slash drug prices

As AI in medicine takes off, can 'human in the loop' prevent harm?

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

AI models in health care face new federal disclosure requirements

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

How many hemophilia patients actually want gene therapy?

In age of alternative facts, a scholarly course on calling out crap

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Activists slam private health insurers over coverage restrictions

How to save health care price transparency rules

Hepatitis C has a cure — but many Americans still lack access to it

Pregnancy discrimination could be enabled by AI

explore

Why scientists need input from humanists on sensitive research

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

CMS should re

Pharma patents targeted by Biden in move to slash drug prices

Why depression after traumatic brain injury is distinct

focus

Wikipedia

focus

knowledge